Wir sind mit live! Mehr erfahren
TWST-Symbol

Twist Bioscience

132,75 USD
-11,74
8,13 %
Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT
Vor Börsenbeginn
Nachbörslich
131,00
-1,75
1,32 %
1 Tag
-8,13 %
5 Tage
-16,92 %
1 Monat
-7,21 %
3 Monate
45,51 %
6 Monate
136,08 %
Seit Jahresbeginn
309,85 %
1 Jahr
331,71 %
5 Jahre
17,36 %
10 Jahre
848,21 %
 

Profil: Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.

Mitarbeiter: 979

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 35,7 %
Neutral 60,7 %
Negativ 3,6 %
Negativ
Seeking Alpha
vorgestern
Polen 5Perspectives Small-Mid Growth Q3 2026 Portfolio Update
During Q3 2026, the Polen 5Perspectives Small-Mid Growth Composite Portfolio returned -12.5% (net of fees) compared to the -10.4% return of the Russell 2500 Growth Index. The top contributors to the Portfolio's relative performance in the quarter were Twist Bioscience, Twilio, and Embraer. The most significant detractors from the Portfolio's relative performance in the quarter were nLight, Terawulf, and BWX Technologies.
Polen 5Perspectives Small-Mid Growth Q3 2026 Portfolio Update
Neutral
ETF Trends
vor 3 Tagen
How to Invest in AI Drug Discovery
.Danaher (DHR), one of the world's largest providers of medical diagnostics and laboratory equipment, recently announced plans to launch its first AI-powered autonomous laboratory, scheduled to operate at commercial scale in early 2027. While market trading barely moved the stock on the announcement date, the news marks a quiet turning point for life science automation.
How to Invest in AI Drug Discovery
Positiv
The Motley Fool
vor 5 Tagen
These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?
Moderna's stock has skyrocketed on exciting results from its personalized cancer vaccine. Twist Bioscience's synthetic DNA is enjoying strong demand.
These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?
Positiv
ETF Trends
vor 17 Tagen
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).
The Top HealthTech Questions Landing on Our Desks
Neutral
Benzinga
vor 22 Tagen
Twist Bioscience Stock Hits New High, Then Retreats: What's Happening?
Twist Bioscience Corp. (NASDAQ:TWST) shares are trading lower Friday, pulling back after touching a fresh 52-week high near $192 earlier in the session. Here's what you should know.
Twist Bioscience Stock Hits New High, Then Retreats: What's Happening?
Neutral
InvestorPlace
vor 25 Tagen
3 Analysts, 3 Trades to Make Today
Louis says buy the AI dip
3 Analysts, 3 Trades to Make Today
Positiv
The Motley Fool
vor 28 Tagen
Why Twist Bioscience Stock Skyrocketed This Week
The biotech will both contribute to and draw from its findings. It'll also earn revenue from its participation.
Why Twist Bioscience Stock Skyrocketed This Week
Positiv
Benzinga
letzten Monat
Beyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab Ecosystem
Twist Bioscience Corporation (NASDAQ:TWST) on Wednesday announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Co. (NYSE:LLY).
Beyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab Ecosystem
Positiv
Benzinga
letzten Monat
LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Nasdaq Composite gaining around 150 points on Wednesday.
LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday
Neutral
Business Wire
letzten Monat
Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). Twist is a provider of antibody characterization data services for TuneLab, including for AbLab, an antibody developability prediction model. TuneLab was created to accelerate biotech innovation by enabling participating compan.
Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery
Kursdiagramme mit Lightweight Charts™ umgesetzt